Compare Stocks

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSAQ Health Sciences Acquisitions Co. 2	$4.62 -0.9%	$5.75	$9.41 ▼ $13.80	$51.80M	0.09	205,918 shs	16,273 shs
KRMD KORU Medical Systems	$2.05 -3.3%	$2.19	$1.98 ▼ $4.48	$93.71M	0.53	96,006 shs	38,728 shs
NYXH Nyxoah	$10.08 +5.5%	$13.68	$4.00 ▼ $20.00	N/A	1.5	57,861 shs	15,864 shs
OBIO Orchestra BioMed	$4.69 +1.5%	$5.73	$4.26 ▼ $20.69	$167.81M	0.15	49,853 shs	18,340 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSAQ Health Sciences Acquisitions Co. 2	-0.86%	-5.52%	-13.81%	-38.15%	-76.64%
KRMD KORU Medical Systems	-1.40%	-0.93%	+1.92%	+2.42%	-47.00%
NYXH Nyxoah	+2.69%	-10.08%	-51.03%	+126.84%	-2.10%
OBIO Orchestra BioMed	-0.86%	-5.52%	-13.81%	-38.65%	-76.64%

Nvidia Has a BIG Problem — Here’s Who Benefits MOST (Ad)

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRMD KORU Medical Systems	1.9956 of 5 stars	3.5	1.0	0.0	0.0	2.9	2.5	0.6
NYXH Nyxoah	2.7636 of 5 stars	4.4	4.0	0.0	0.0	2.3	0.8	0.0
OBIO Orchestra BioMed	0.6655 of 5 stars	3.5	2.0	0.0	0.0	0.0	0.8	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A
KRMD KORU Medical Systems	3.00	Buy	$3.50	70.73% Upside
NYXH Nyxoah	2.83	Moderate Buy	$20.60	104.37% Upside
OBIO Orchestra BioMed	3.00	Buy	$17.00	262.47% Upside

Current Analyst Ratings

Latest NYXH, HSAQ, OBIO, and KRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2024	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/20/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $22.00
3/20/2024	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
3/14/2024	KRMD KORU Medical Systems	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
3/14/2024	NYXH Nyxoah	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $20.00
3/6/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
3/6/2024	NYXH Nyxoah	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$15.00 ➝ $20.00
3/5/2024	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
2/28/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $18.00
2/9/2024	NYXH Nyxoah	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
2/1/2024	NYXH Nyxoah	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $15.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
KRMD KORU Medical Systems	$28.52M	3.29	N/A	N/A	$0.45 per share	4.56
NYXH Nyxoah	$4.70M	N/A	N/A	N/A	$5.08 per share	N/A
OBIO Orchestra BioMed	$2.76M	60.80	N/A	N/A	$1.90 per share	2.47

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	0.00	∞	N/A	N/A	N/A	-2.38%	N/A
KRMD KORU Medical Systems	-$13.74M	-$0.29	N/A	N/A	N/A	-48.18%	-27.82%	-21.30%	5/1/2024 (Confirmed)
NYXH Nyxoah	-$46.77M	-$1.68	N/A	N/A	N/A	-993.28%	-38.58%	-31.24%	5/21/2024 (Estimated)
OBIO Orchestra BioMed	-$49.12M	-$1.50	N/A	N/A	N/A	-1,779.71%	-58.32%	-41.47%	5/10/2024 (Estimated)

Latest NYXH, HSAQ, OBIO, and KRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2024	N/A	KRMD KORU Medical Systems	-$0.04	N/A	+$0.04	N/A	N/A	N/A
3/27/2024	Q4 2023	OBIO Orchestra BioMed	-$0.38	-$0.37	+$0.01	-$0.37	$1.00 million	$0.26 million
3/13/2024	Q4 2023	KRMD KORU Medical Systems	-$0.04	-$0.02	+$0.02	$0.12	$7.01 million	$7.19 million
3/5/2024	Q4 2023	NYXH Nyxoah	-$0.41	-$0.41	N/A	-$0.41	$2.01 million	$1.96 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
KRMD KORU Medical Systems	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
KRMD KORU Medical Systems	0.02	4.55	3.77
NYXH Nyxoah	0.12	4.73	4.50
OBIO Orchestra BioMed	N/A	7.95	7.94

Ownership

Institutional Ownership

Company	Institutional Ownership
HSAQ Health Sciences Acquisitions Co. 2	89.71%
KRMD KORU Medical Systems	58.60%
NYXH Nyxoah	N/A
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
HSAQ Health Sciences Acquisitions Co. 2	21.90%
KRMD KORU Medical Systems	25.60%
NYXH Nyxoah	17.11%
OBIO Orchestra BioMed	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
KRMD KORU Medical Systems	82	45.71 million	34.01 million	Optionable
NYXH Nyxoah	137	N/A	N/A	Not Optionable
OBIO Orchestra BioMed	56	35.78 million	N/A	Not Optionable

NYXH, HSAQ, OBIO, and KRMD Headlines

Source	Headline
	Comparing Orchestra BioMed (OBIO) and Its Peers americanbankingnews.com - April 15 at 1:50 AM
	Orchestra BioMed: Continuing the Momentum into a Promising Future msn.com - March 31 at 11:03 PM
	Orchestra BioMed Bolsters Board with Healthcare Industry Veteran David Pacitti msn.com - March 31 at 12:42 PM
	Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 29 at 8:20 AM
	Orchestra BioMed's (OBIO) Buy Rating Reaffirmed at Chardan Capital marketbeat.com - March 28 at 9:24 AM
	Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data markets.businessinsider.com - March 28 at 2:13 AM
	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023 investorplace.com - March 27 at 11:03 PM
	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update globenewswire.com - March 27 at 4:17 PM
	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors globenewswire.com - March 26 at 8:00 AM
	Orchestra BioMed's AVIM Therapy Demonstrates Promising Results in Controlling Hypertension msn.com - March 11 at 8:00 AM
	Orchestra BioMed to Participate in Upcoming Investor Conferences globenewswire.com - March 7 at 8:00 AM
	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients globenewswire.com - March 6 at 8:37 AM
	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season finance.yahoo.com - February 16 at 2:24 PM
	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season zacks.com - February 16 at 10:16 AM
	Orchestra BioMed Hldgs Stock (NASDAQ:OBIO), Short Interest Report benzinga.com - January 19 at 9:01 PM
	Jefferies starts Orchestra BioMed at buy, cites lead program opportunities msn.com - January 19 at 9:01 PM
	Orchestra BioMed Holdings Inc OBIO morningstar.com - January 16 at 10:41 AM
	Orchestra BioMed begins pivotal trial of cardiac neuromod tech massdevice.com - January 8 at 6:55 PM
	Silicon Box Accelerates Industry Leadership With Production Commencement at its World Leading Advanced Packaging Facility and Series B Fundraising sg.finance.yahoo.com - January 8 at 8:54 AM
	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has caught the attention of hedge funds investors who hold a sizeable 28% stake finance.yahoo.com - January 3 at 12:03 PM
	BATL, SNCR and BVN are among pre market gainers msn.com - December 18 at 11:06 AM
	Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update finanznachrichten.de - November 16 at 9:27 AM
	Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC) markets.businessinsider.com - November 14 at 3:03 PM
	Orchestra BioMed Holdings, Inc. (OBIO) uk.finance.yahoo.com - November 14 at 10:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Health Sciences Acquisitions Co. 2

NASDAQ:HSAQ

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

KORU Medical Systems

NASDAQ:KRMD

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

Nyxoah

NASDAQ:NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Orchestra BioMed

NASDAQ:OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial